Expanding The Spectrum Of Biomarkers For Heart Disease: Homocysteine, Us Crp And Lipoprotein(A)

Abstract

Taking into consideration that frequently cardiovascular patients do not present major risk factors, there remains a residual risk that can be, at least in part, measured by biomarkers of thrombosis and inflammation, based on clinical trials and clinical observations. This paper presents the role of three biomarkers - Homocysteyne, ultra sensitive C-Reactive Protein and Lipoprotein(a). The official Cardiac and Atherosclerosis Medical Societies conducts expert meetings that publish Recommendations for each of them. These Recommendations may help and guide clinicians as to their decision making regarding prevention of atherosclerotic cardiovascular diseases. Regarding hyperhomocysteinemia a healthy diet is the first choice, before prescribing folic acid and B vitamins supplements. A physician taking any type of nutritional approach to reducing risk should consider a person's overall risk factor profile and personalized diet. As for the inflammatory marker ultra sensitive C-Reactive Protein there is a strong association with risk of fatal vascular events than non fatal vascular events.